Regeneron Pharmaceuticals (REGN)
Health Care · Biotechnology · NASDAQ
Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company utilizes proprietary technology platforms, including human genetics research, to advance a pipeline of product candidates across various therapeutic areas. It also collaborates with major pharmaceutical partners like Sanofi and Bayer to develop and market several of its products.
Themes: biotechnology, human genetics research, drug development and commercialization
Fundamentals
- Price$739.57 as of 2026-10-08 close
- Market cap$69.5B as of 2012-07-13 (share count; price 2026-10-08)
- 1-year return+31.2% 2025-10-08 close $563.86 → 2026-10-08 close $739.57
- P/E18.28 as of 2026-10-08
- Net margin+31.4% FY2025, SEC XBRL
- ROE+14.4% FY2025, SEC XBRL
- Debt / equity0.09 as of 2026-09-02
- Revenue growth (YoY)+9.3% as of 2026-09-02
- Revenue CAGR (3y)+5.6% SEC XBRL
- Beta0.61 as of 2026-09-02
- Last reported earnings2026-10-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.5%; pays a dividend.
How REGN compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 10% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 25% 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
REGN is in the Top 10 — Health Care.
Top 10 — Health Care — since 1 Oct 2026
Top 10 score
68.2 #52 of 1,379 scored · #6 of 151 in Health Care
Capital return 93rd (net share count bought back over the year 5.7) and financial health 85th (free cash flow margin 28.4%, debt to equity 0.1); weakest is growth (48th, 3-year revenue CAGR 5.6%, revenue growth year over year 9.3%).
In this list since 1 Oct 2026 — currently 6th in the list (7 days)
- Entered 1 Oct 2026: score 67.9, rank 7 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, REGN's dividend was covered by reported results (earnings payout 8%, free-cash-flow payout 9%). This describes past coverage, not a forecast.
- Earnings payout8% dividends / net income
- Free-cash-flow payout9% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Regeneron Pharmaceuticals looks technically
Regeneron Pharmaceuticals (REGN) is trading 0.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 25 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 0.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $789.53 | $789.53 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $737.88 | $737.88 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 813.53. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 25 trading days ago — a "golden cross", a bullish long-term signal | 25 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.2% above | +0.2% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 39, neither overbought (above 70) nor oversold (below 30) | 38.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($722.02 to $813.53) — its "stochastic" reading is 19 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 19.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 31 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $859.34 | $859.34 |
|---|---|---|
| From the 52-week high | it is 13.9% below its 52-week high (its highest price of the past year) | -13.9% |
| Above the 52-week low | it is 36.7% above its 52-week low (its lowest price of the past year) | +36.7% |
| Below the 52-week high | it is 13.9% below its highest point of the past year | 13.9% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 26 trading days ago | 26 sessions |
| All-time high | its highest closing price on record is $1211.20 (set on 2024-08-27) | $1211.20 |
| Given back of the 52-week move | over the past year its closes ranged ($557.73 to $852.03), and it has given back roughly a third of its rise from last year’s low — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $660.74 to $670.15. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.2% |
| From the all-time high | it is 38.9% below its all-time high | -38.9% |
| Nearest price level | it is trading 1.0% above a support level at $731.86 — a price it turned at 8 times since 2024-11-21, most recently on 2026-05-13. Since 2024-10-08 it has 9 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $4.61 (set on 2005-04-12) | $4.61 |
| Above the all-time low | it is 15942.7% above its all-time low | +15,943% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $20.56 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $20.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $717.05 and $819.36 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $717.05 – $768.21 – $819.36 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges above its 200-day average price (0.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.69× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.07 toward buy |
Candlestick patterns
1
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
|---|
Price gaps
1
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 8.7% while the market gained 1.0%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 7.7 percentage points (the stock gained 11.6% while the market gained 3.8%) | +7.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.5 percentage points (the stock lost 3.1% while the market gained 17.5%) | -20.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.2 percentage points (the stock gained 31.2% while the market gained 15.0%) | +16.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 9.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $725.29 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +2.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-07-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $756.47 — a volume-weighted average of daily closes over 68 sessions, not a true tick-by-tick VWAP. | -2.2% |
Price levels it has turned at before
REGN last closed at $739.57 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $731.86 | Support | 1.0% below the last close | turned there 8 times · 2024-11-21 to 2026-05-13 |
| $748.73 | Resistance | 1.2% above the last close | turned there five times · 2025-01-08 to 2026-02-26 |
| $774.66 | Resistance | 4.8% above the last close | turned there five times · 2026-01-27 to 2026-09-15 |
| $694.11 | Support | 6.2% below the last close | turned there four times · 2024-12-19 to 2026-07-17 |
| $794.88 | Resistance | 7.5% above the last close | turned there four times · 2024-12-09 to 2026-03-03 |
| $665.62 | Support | 10.0% below the last close | turned there five times · 2025-01-13 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $813.53.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $668.28 and $723.76 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $813.53.
This reading has stood for 7 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · lagging the market · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.85 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$853.19 range $730.00 – $1,030.00; median $857.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for REGN
- Consensus EPS estimate$15.99 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.00496 (-0.0%) from $16.00, on 2026-08-31, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition from biosimilar products and alternative treatments that may be more cost-effective.","Uncertainty regarding regulatory approvals, clinical trial outcomes, and the commercial success of new product candidates.","Risks related to drug pricing regulations, legislative changes, and potential limitations on reimbursement from government and private payors."]
What changed in the latest 10-Q
AI-assisted comparison of REGN's 10-Q filed 2026-04-29 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'April 2026 agreements with the U.S. government' in drug pricing strategy risk factor (filed 2026-04-29)
- Added specific language 'including in connection with our April 2026 agreements with the U.S. government discussed in this report' to drug pricing regulations risk factor (filed 2026-04-29)
- Removed:
- Removed phrase 'including without limitation capital expenditures' from the financial projections risk factor (filed 2025-10-28)
- Removed nine-month financial data from Selected financial information table; Q3 2025 vs Q3 2024 comparison retained in older filing (filed 2025-10-28)
- Changed quarter comparison from 'Three Months Ended September 30' with 2025/2024 data to 'Three Months Ended March 31' with 2026/2025 data
- Reworded:
- Changed 'competing drugs and product candidates' to 'competing products and product candidates' and reordered biosimilar reference from end of bullet to beginning (filed 2026-04-29)
- Changed 'our ability to meet any of our financial projections or guidance' to 'our ability to meet any of our financial projections or guidance and changes to the assumptions underlying those projections or guidance' with removal of capital expenditures clause (filed 2026-04-29)
- Notes:
- Financial data comparison reflects different reporting periods (Q1 2026 vs Q3 2025 vs Q3 2024) and different comparative years
- Text appears truncated at end of both filings, limiting full assessment of later sections
Risk Factors
- Added:
- In newer filing (2026-04-29): Commercialization Risks bullet changed from 'We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent' to 'We are substantially dependent on revenues derived from net product sales of EYLEA HD, EYLEA, and Dupixent' (reordering of products and addition of 'revenues derived from net product sales of')
- Removed:
- In older filing (2025-10-28): Regulatory and Development Risks bullet stated 'Drug development and obtaining and maintaining regulatory approval for drug products' whereas newer filing changes 'drug products' to 'drug and biological products'
- In older filing (2025-10-28): Manufacturing and Supply Risks bullet stated 'in anticipation of a potential regulatory approval' whereas newer filing removes 'a' before 'potential'
- In older filing (2025-10-28): Manufacturing and Supply Risks bullet stated third-party failures 'would adversely affect' whereas newer filing changes to 'could adversely affect'
- In older filing (2025-10-28): Other Regulatory and Litigation Risks section continues with text about employee conduct that is cut off in newer filing excerpt
- Reworded:
- Commercialization Risks: Product order changed from 'EYLEA, EYLEA HD, and Dupixent' (2025-10-28) to 'EYLEA HD, EYLEA, and Dupixent' (2026-04-29); substance changed from 'dependent on the success of' to 'dependent on revenues derived from net product sales of'
- Regulatory and Development Risks: 'drug products' expanded to 'drug and biological products' (2026-04-29)
- Manufacturing and Supply Risks: 'in anticipation of a potential regulatory approval' simplified to 'in anticipation of potential regulatory approvals' (2026-04-29)
- Manufacturing and Supply Risks: 'would adversely affect' changed to 'could adversely affect' (2026-04-29)
- Notes:
- The newer filing excerpt appears to be truncated at 'If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be' and does not include the complete sentence or subsequent risk factors present in the older filing
- Comparison is limited to the provided excerpts; full section content may contain additional changes not visible in these truncated versions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 5 sells ($3M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 18 sells ($4M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-03. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about REGN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 13 matched disclosures for REGN from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding REGN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 16,166,721
- Reported value $10,080,597,977
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about REGN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
REGN had 2,526,446 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for REGN because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 2,526,446
- Prior settlement (shares) 2,552,029
- Reported change -1%
- Days to cover (reported) 4.42
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Bayer (BAYRY)
- Roche (RHHBY)
- Amgen (AMGN)
- AbbVie (ABBV)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare REGN vs…
Regeneron Pharmaceuticals is found in…
Frequently asked questions
What does Regeneron Pharmaceuticals (REGN) do?
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious medical conditions. The company utilizes proprietary technology platforms, including human genetics research, to advance a pipeline of product candidates across various therapeutic areas. It also collaborates with major pharmaceutical partners like Sanofi and Bayer to develop and market several of its products.
What sector is Regeneron Pharmaceuticals (REGN) in?
Regeneron Pharmaceuticals (REGN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Does REGN pay a dividend?
Yes — Regeneron Pharmaceuticals (REGN) pays a dividend, with an indicated yield of about 0.48% (market data, as of 2026-09-02). Informational only — not financial advice.
Who are Regeneron Pharmaceuticals's (REGN) competitors?
Notable peers of Regeneron Pharmaceuticals (REGN) include Sanofi, Bayer, Roche, Amgen and AbbVie. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in REGN?
Yes — we hold 13 matched STOCK Act disclosures for REGN from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Regeneron Pharmaceuticals (REGN) overbought or oversold right now?
Regeneron Pharmaceuticals (REGN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 39, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on REGN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.